Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Amgen's Phase 2 extension study of Prolia (denosumab) has demonstrated an increase in bone mineral density (BMD) in postmenopausal women.
Subscribe to our email newsletter
The trial results showed BMD at the lumbar spine and total hip increased on average by 16.8% and 6.9% in comparison to baseline, respectively.
The Phase 2 extension study aimed to establish the effects of up to eight years of continued treatment with Prolia on BMD and bone turnover markers in postmenopausal women with low bone mass or osteoporosis.
Oregon Osteoporosis Center founding director Michael McClung said this study provides additional data that Prolia continues to increase bone mineral density progressively over a treatment period of eight years.